

**Table S1:** Demographic and clinical characteristics of multiple sclerosis patients according to different disease courses

|  | Whole cohort |                  | CIS |              | McDonalds MS |                 | RRMS |                | SPMS |                 | PPMS |                | P value                      |
|--|--------------|------------------|-----|--------------|--------------|-----------------|------|----------------|------|-----------------|------|----------------|------------------------------|
|  | n            |                  | n   |              | n            |                 | n    |                | n    |                 | n    |                |                              |
| <b>Demographics</b>                            |              |                  |     |              |              |                 |      |                |      |                 |      |                |                              |
| Age at disease onset (years) <sup>1</sup>      | 540          | 31 (19-48)       | 80  | 29 (21-52)   | 239          | 32 (20-47)      | 157  | 28 (18-44)     | 19   | 31 (15-48)      | 45   | 43 (28-58)     | <b>&lt;0.001<sup>3</sup></b> |
| Age at LP (years) <sup>1</sup>                 | 541          | 34 (21-54)       | 80  | 29 (21-52)   | 240          | 33 (21-48)      | 157  | 34 (21-51)     | 19   | 47 (32-69)      | 45   | 47 (32-63)     | <b>&lt;0.001<sup>3</sup></b> |
| Sex (females) <sup>2</sup>                     | 541          | 376 (70)         | 80  | 49 (61)      | 240          | 176 (73)        | 157  | 115 (73)       | 19   | 13 (68)         | 45   | 23 (51)        | <b>0.014<sup>4</sup></b>     |
| <b>Clinical characteristics</b>                |              |                  |     |              |              |                 |      |                |      |                 |      |                |                              |
| Disease duration until LP (years) <sup>1</sup> | 540          | 0.27 (0.01-16.2) | 80  | 0.03 (0-0.5) | 239          | 0.05 (0.01-1.5) | 157  | 3.7 (0.3-20.0) | 19   | 17.2 (0.8-48.2) | 45   | 2.9 (0.4-15.2) | <b>&lt;0.001<sup>3</sup></b> |
| <b>MRI findings at baseline</b>                |              |                  |     |              |              |                 |      |                |      |                 |      |                |                              |
| DIS/ no DIT by MRI <sup>2</sup>                |              |                  | 80  | 3 (4)        | 240          | 72 (30)         |      |                |      |                 |      |                |                              |
| DIT/ no DIS by MRI <sup>2</sup>                |              |                  | 80  | 21 (26)      | 0            | 0 (0)           |      |                |      |                 |      |                |                              |
| DIS & DIT by MRI <sup>2</sup>                  |              |                  | 80  | 0 (0)        | 240          | 168 (70)        |      |                |      |                 |      |                |                              |
| DIS by MRI and DIT by OCB <sup>2</sup>         |              |                  | 80  | 0 (0)        | 240          | 72 (30)         |      |                |      |                 |      |                |                              |

Legend:

Data are shown as <sup>1</sup>median (5<sup>th</sup>-95<sup>th</sup> percentile) or <sup>2</sup>n (%). Group comparison were performed by <sup>3</sup>Kruskal-Wallis test or <sup>4</sup>Pearson Chi-Quadrat test. P-values <0.05 are marked bold.

**Abbreviations:** CIS, clinically isolated syndrome; DIS, dissemination in space; DIT, dissemination in time; LP, lumbar puncture; MRI, magnetic resonance imaging; MS, multiple sclerosis; OCB, oligoclonal bands; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis

**Table S2:** Demographic and clinical characteristics of patients with a first clinical attack according to MRI criteria of DIS and DIT

|   | DIS |                | DIT |               | DIS & DIT |                | No DIS or DIT |               | P value                      |
|---|-----|----------------|-----|---------------|-----------|----------------|---------------|---------------|------------------------------|
|   | n   |                | n   |               | n         |                | n             |               |                              |
| <b>Demographics</b>   |     |                |     |               |           |                |               |               |                              |
| Age at disease onset (years) <sup>1</sup>                           | 75  | 35 (21-50)     | 21  | 32 (19-57)    | 167       | 30 (20-47)     | 56            | 28 (21-49)    | <b>&lt;0.001<sup>3</sup></b> |
| Age at LP (years) <sup>1</sup>                                      | 75  | 36 (21-51)     | 21  | 33 (19-57)    | 168       | 30 (21-47)     | 56            | 28 (21-49)    | <b>&lt;0.001<sup>3</sup></b> |
| Sex (female) <sup>2</sup>   | 75  | 60 (80)        | 21  | 12 (57)       | 168       | 117 (70)       | 56            | 36 (64)       | 0.106 <sup>4</sup>           |
| <b>Clinical characteristics</b>                                     |     |                |     |               |           |                |               |               |                              |
| Disease duration until LP (months)                                  | 75  | 0.9 (0.1-37.4) | 21  | 0.3 (0-6.2)   | 167       | 0.6 (0.1-16.9) | 56            | 0.6 (0-5.5)   | 0.848                        |
| 2 <sup>nd</sup> relapse <sup>2</sup>                                | 51  | 33 (65)        | 15  | 12 (80)       | 145       | 117 (81)       | 37            | 29 (78)       | 0.134 <sup>4</sup>           |
| Disease duration until 2 <sup>nd</sup> relapse (years) <sup>1</sup> | 33  | 1.7 (0.2-9.8)  | 12  | 1.5 (0.2-7.2) | 116       | 1.3 (0.2-8.1)  | 29            | 1.8 (0.2-6.6) | 0.933 <sup>3</sup>           |

Legend:

Data are shown as <sup>1</sup>median (5<sup>th</sup>-95<sup>th</sup> percentile) or <sup>2</sup>n (%). Group comparison were performed by <sup>3</sup>Kruskal-Wallis test or <sup>4</sup>Pearson Chi-Quadrat test. P-values <0.05 are marked bold.

*Abbreviations:* DIS, dissemination in space; DIT, dissemination in time; LP, lumbar puncture

**Table S3:** Demographic and clinical characteristics of patients with a first clinical attack according to the occurrence of a second relapse during follow-up

|   | No relapse     | Relapse         | P value             |
|---|----------------|-----------------|---------------------|
| n   | 29             | 74              |                     |
| <b>Demographics</b>   |                |                 |                     |
| Age at disease onset (years) <sup>1</sup>                           | 34 (20-42)     | 31 (19-46)      | 0.514 <sup>3</sup>  |
| Age at LP (years) <sup>1</sup>                                      | 34 (20-42)     | 31 (19-46)      | 0.562 <sup>3</sup>  |
| Sex (female) <sup>2</sup>   | 21 (72)        | 53 (72)         | 0.936 <sup>4</sup>  |
| <b>MRI findings at baseline</b>                                     |                |                 |                     |
| DIS <sup>2</sup>  | 18 (62)        | 33 (45)         | 0.278 <sup>4</sup>  |
| DIT <sup>2</sup>  | 3 (10)         | 12 (16)         |                     |
| No DIS no DIT <sup>2</sup>  | 8 (28)         | 29 (39)         |                     |
| <b>Clinical characteristics</b>                                     |                |                 |                     |
| Disease duration before LP (months) <sup>1</sup>                    | 0.8 (0-11.5)   | 0.6 (0-12.7)    | 0.792 <sup>3</sup>  |
| Follow-up duration (years) <sup>1</sup>                             | 5.8 (0.8-12.3) | 10.0 (2.0-16.1) | <0.001 <sup>3</sup> |
| Disease duration until 2 <sup>nd</sup> relapse (years) <sup>1</sup> | NA             | 1.6 (0.2-7.4)   | NA                  |

Legend:

Data are shown as <sup>1</sup>median (5<sup>th</sup>-95<sup>th</sup> percentile) or <sup>2</sup>n (%). Group comparison were performed by <sup>3</sup>Mann-Whitney U test or <sup>4</sup>Pearson Chi-Quadrat test. P-values <0.05 are marked bold.

*Abbreviations:* DIS, dissemination in space; DIT, dissemination in time; LP, lumbar puncture; MRI, magnetic resonance imaging; NA, not appropriate

**Table S4:** Correlation of various cerebrospinal fluid findings

|                                  |         | <b>CSF TP (mg/l)</b> | <b>Q<sub>alb</sub></b> | <b>IF IgG Reiber (%)</b> | <b>IF IgG Auer&amp;Hegen (%)</b> | <b>IF IgA Reiber (%)</b> | <b>IF IgA Auer&amp;Hegen (%)</b> | <b>IF IgM Reiber (%)</b> | <b>IF IgM Auer&amp;Hegen (%)</b> | <b>Age<sup>1</sup> (years)</b> | <b>Disease duration<sup>1</sup> (years)</b> |
|----------------------------------|---------|----------------------|------------------------|--------------------------|----------------------------------|--------------------------|----------------------------------|--------------------------|----------------------------------|--------------------------------|---|
| <b>WBC (/µl)</b>                 | r       | 0.220                | 0.111                  | 0.427                    | 0.459                            | 0.119                    | 0.137                            | 0.237                    | 0.240                            | -0.282                         | -0.135                                      |
|                                  | p-value | <b>&lt;0.001</b>     | <b>0.011</b>           | <b>&lt;0.001</b>         | <b>&lt;0.001</b>                 | <b>0.007</b>             | <b>0.002</b>                     | <b>&lt;0.001</b>         | <b>&lt;0.001</b>                 | <b>&lt;0.001</b>               | <b>0.002</b>                                |
|                                  | n       | 540                  | 527                    | 527                      | 527                              | 517                      | 517                              | 527                      | 527                              | 541                            | 540   |
| <b>CSF TP (mg/l)</b>             | r       |                      | 0.794                  | -0.046                   | 0.054                            | -0.128                   | -0.025                           | -0.200                   | -0.185                           | 0.165                          | 0.158                                       |
|                                  | p-value |                      |                        | <b>&lt;0.001</b>         | 0.289                            | 0.215                    | <b>0.004</b>                     | 0.569                    | <b>&lt;0.001</b>                 | <b>&lt;0.001</b>               | <b>&lt;0.001</b>                            |
|                                  | n       |                      | 526                    | 526                      | 526                              | 516                      | 516                              | 526                      | 526                              | 540                            | 539   |
| <b>Q<sub>alb</sub></b>           | r       |                      |                        | -0.323                   | -0.208                           | -0.160                   | -0.048                           | -0.260                   | -0.247                           | 0.224                          | 0.153                                       |
|                                  | p-value |                      |                        |                          | <b>&lt;0.001</b>                 | <b>&lt;0.001</b>         | <b>&lt;0.001</b>                 | 0.272                    | <b>&lt;0.001</b>                 | <b>&lt;0.001</b>               | <b>&lt;0.001</b>                            |
|                                  | n       |                      |                        | 527                      | 527                              | 517                      | 517                              | 527                      | 527                              | 527                            | 526   |
| <b>IF IgG Reiber (%)</b>         | r       |                      |                        |                          | 0.991                            | 0.341                    | 0.304                            | 0.390                    | 0.385                            | -0.063                         | 0.028                                       |
|                                  | p-value |                      |                        |                          |                                  | <b>&lt;0.001</b>         | <b>&lt;0.001</b>                 | <b>&lt;0.001</b>         | <b>&lt;0.001</b>                 | 0.146                          | 0.528                                       |
|                                  | n       |                      |                        |                          | 527                              | 517                      | 517                              | 527                      | 527                              | 527                            | 526   |
| <b>IF IgG Auer&amp;Hegen (%)</b> | r       |                      |                        |                          |                                  | 0.328                    | 0.306                            | 0.367                    | 0.364                            | -0.038                         | 0.052                                       |
|                                  | p-value |                      |                        |                          |                                  |                          | <b>&lt;0.001</b>                 | <b>&lt;0.001</b>         | <b>&lt;0.001</b>                 | 0.379                          | 0.231                                       |
|                                  | n       |                      |                        |                          |                                  | 517                      | 517                              | 527                      | 527                              | 527                            | 526   |
| <b>IF IgA Reiber (%)</b>         | r       |                      |                        |                          |                                  |                          | 0.985                            | 0.530                    | 0.523                            | -0.126                         | -0.073                                      |
|                                  | p-value |                      |                        |                          |                                  |                          |                                  | <b>&lt;0.001</b>         | <b>&lt;0.001</b>                 | <b>&lt;0.001</b>               | 0.098                                       |
|                                  | n       |                      |                        |                          |                                  |                          | 517                              | 517                      | 517                              | 517                            | 516   |
| <b>IF IgA Auer&amp;Hegen (%)</b> | r       |                      |                        |                          |                                  |                          |                                  | 0.499                    | 0.500                            | -0.107                         | -0.047                                      |
|                                  | p-value |                      |                        |                          |                                  |                          |                                  |                          | <b>&lt;0.001</b>                 | <b>&lt;0.001</b>               | <b>0.015</b>                                |
|                                  | n       |                      |                        |                          |                                  |                          |                                  | 517                      | 517                              | 517                            | 516   |
| <b>IF IgM Reiber (%)</b>         | r       |                      |                        |                          |                                  |                          |                                  |                          | 0.997                            | -0.156                         | -0.091                                      |
|                                  | p-value |                      |                        |                          |                                  |                          |                                  |                          |                                  | <b>&lt;0.001</b>               | <b>&lt;0.001</b>                            |
|                                  | n       |                      |                        |                          |                                  |                          |                                  |                          | 527                              | 527                            | 526   |

|                       |         |  |  |  |  |  |  |  |                  |        |
|-----------------------|---------|--|--|--|--|--|--|--|------------------|--------|
| IF IgM Auer&Hegen (%) | r       |  |  |  |  |  |  |  | -0.158           | -0.079 |
|                       | p-value |  |  |  |  |  |  |  | <b>&lt;0.001</b> | 0.07   |
|                       | n       |  |  |  |  |  |  |  | 527              | 526    |

Legend:

<sup>1</sup> Patients' age and disease duration was determined at the time of lumbar puncture. P-values <0.05 are marked bold.

*Abbreviations:* CSF, cerebrospinal fluid; IF, intrathecal fraction; Ig, immunoglobulin; n, number of patients; Q<sub>alb</sub>, CSF/ serum albumin quotient; r, correlation coefficient; TP, total protein; WBC, white blood cell

**Table S5:** Linear regression analysis to identify predictors of CSF white blood cells

| Variable                     | Coefficient | SE    | 95% CI |        | P value          |
|------------------------------|-------------|-------|--------|--------|------------------|
| Sex <sup>1</sup>             | -0.274      | 0.098 | -0.466 | -0.081 | <b>0.005</b>     |
| Age (years)                  | -0.704      | 0.167 | -1.032 | -0.375 | <b>&lt;0.001</b> |
| Disease duration (years)     | -0.045      | 0.030 | -0.104 | 0.014  | 0.138            |
| <i>Diagnosis<sup>2</sup></i> |             |       |        |        |                  |
| CIS                          | 0.477       | 0.233 | 0.019  | 0.934  | <b>0.041</b>     |
| McDonald MS                  | 0.682       | 0.204 | 0.281  | 1.083  | <b>0.001</b>     |
| RRMS                         | 0.821       | 0.183 | 0.462  | 1.179  | <b>&lt;0.001</b> |
| SPMS                         | 0.502       | 0.286 | -0.059 | 1.063  | 0.079            |
| Constant                     | 3.627       | 0.653 | 2.344  | 4.909  | <0.001           |

Legend:

The dependent variable WBC count (/μl) and the independent variables age (determined at the time of lumbar puncture) and disease duration (time between symptom onset and lumbar puncture) were log-transformed to achieve normal distribution.

Reference categories were <sup>1</sup> male sex and <sup>2</sup> PPMS. P-values <0.05 are marked bold.

*Abbreviations:* CI, confidence interval; CIS, clinically isolated syndrome; CSF, cerebrospinal fluid; MS, multiple sclerosis; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SE, standard error; WBC, white blood cell

**Table S6:** Linear regression analysis to identify predictors of Q<sub>alb</sub>

| Variable                     | Coefficient | SE    | 95% CI |        | P value          |
|------------------------------|-------------|-------|--------|--------|------------------|
| Sex <sup>1</sup>             | -0.251      | 0.038 | -0.325 | -0.176 | <b>&lt;0.001</b> |
| Age (years)                  | 0.283       | 0.065 | 0.156  | 0.411  | <b>&lt;0.001</b> |
| Disease duration (years)     | 0.015       | 0.012 | -0.008 | 0.038  | 0.192            |
| <i>Diagnosis<sup>2</sup></i> |             |       |        |        |                  |
| CIS                          | -0.148      | 0.129 | -0.402 | 0.106  | 0.253            |
| McDonald MS                  | -0.040      | 0.121 | -0.278 | 0.198  | 0.740            |
| RRMS                         | -0.039      | 0.109 | -0.254 | 0.176  | 0.722            |
| PPMS                         | -0.191      | 0.120 | -0.426 | 0.044  | 0.111            |
| Constant                     | 0.845       | 0.265 | 0.324  | 1.366  | 0.002            |

Legend:

The dependent variable Q<sub>alb</sub> and the independent variables age (determined at the time of lumbar puncture) and disease duration (time between symptom onset and lumbar puncture) were log-transformed to achieve normal distribution.

Reference categories were <sup>1</sup> male sex and <sup>2</sup> SPMS. P-values <0.05 are marked bold.

*Abbreviations:* CI, confidence interval; CIS, clinically isolated syndrome; MS, multiple sclerosis; PPMS, primary progressive multiple sclerosis; Q<sub>alb</sub>, CSF/ serum albumin quotient; RRMS, relapsing-remitting multiple sclerosis; SE, standard error

**Table S7:** Linear regression analysis to identify predictors of CSF total protein

| Variable                     | Coefficient | SE    | 95% CI |        | P value          |
|------------------------------|-------------|-------|--------|--------|------------------|
| Sex <sup>1</sup>             | -0.191      | 0.030 | -0.251 | -0.132 | <b>&lt;0.001</b> |
| Age (years)                  | 0.141       | 0.052 | 0.039  | 0.244  | <b>0.007</b>     |
| Disease duration (years)     | 0.009       | 0.009 | -0.01  | 0.027  | 0.362            |
| <i>Diagnosis<sup>2</sup></i> |             |       |        |        |                  |
| CIS                          | -0.134      | 0.098 | -0.328 | 0.059  | 0.172            |
| McDonald MS                  | -0.075      | 0.091 | -0.254 | 0.104  | 0.411            |
| RRMS                         | -0.046      | 0.080 | -0.204 | 0.112  | 0.565            |
| PPMS                         | -0.137      | 0.089 | -0.311 | 0.038  | 0.126            |
| Constant                     | 3.396       | 0.211 | 2.982  | 3.810  | <0.001           |

Legend:

The dependent variable CSF total protein and the independent variables age (determined at the time of lumbar puncture) and disease duration (time between symptom onset and lumbar puncture) were log-transformed to achieve normal distribution.

Reference categories were <sup>1</sup> male sex and <sup>2</sup> SPMS. P-values <0.05 are marked bold.

*Abbreviations:* CI, confidence interval; CIS, clinically isolated syndrome; MS, multiple sclerosis; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SE, standard error

**Table S8:** Linear regression analysis to identify predictors of intrathecal IgG synthesis

| Variable                     | Coefficient | SE     | 95% CI  |         | P value      |
|------------------------------|-------------|--------|---------|---------|--------------|
| Sex <sup>1</sup>             | 7.931       | 3.426  | 1.2     | 14.662  | <b>0.021</b> |
| Age (years)                  | -10.07      | 5.846  | -21.556 | 1.416   | 0.086        |
| Disease duration (years)     | 0.042       | 1.054  | -2.029  | 2.113   | 0.968        |
| <i>Diagnosis<sup>2</sup></i> |             |        |         |         |              |
| CIS                          | -36.717     | 11.678 | -59.659 | -13.775 | <b>0.002</b> |
| McDonald MS                  | -22.255     | 10.932 | -43.733 | -0.777  | <b>0.042</b> |
| RRMS                         | -21.908     | 9.86   | -41.279 | -2.537  | <b>0.027</b> |
| PPMS                         | -21.065     | 10.803 | -42.289 | 0.159   | 0.052        |
| Constant                     | 67.494      | 23.946 | 20.448  | 114.54  | 0.005        |

Legend:

The dependent variable was the intrathecal fraction (%) of IgG as determined by the Auer & Hegen formula. The independent variables age (determined at the time of lumbar puncture) and disease duration (time between symptom onset and lumbar puncture) were log-transformed to achieve normal distribution.

Reference categories were <sup>1</sup> male sex and <sup>2</sup> SPMS. P-values <0.05 are marked bold.

*Abbreviations:* CI, confidence interval; CIS, clinically isolated syndrome; IgG, immunoglobulin G; MS, multiple sclerosis; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SE, standard error

**Table S9:** Binary logistic regression analysis to identify predictors of CSF-restricted oligoclonal bands

| Variable                              | Odd's ratio | 95% CI for OR |        | P value      |
|---------------------------------------|-------------|---------------|--------|--------------|
| Sex <sup>1</sup>                      | 1.993       | 0.710         | 5.593  | 0.19         |
| Age (years)                           | 1.018       | 0.961         | 1.078  | 0.552        |
| Disease duration (years)              | 2.315       | 0.185         | 28.932 | 0.515        |
| <i>Brain MRI activity<sup>2</sup></i> |             |               |        |              |
| DIS                                   | 3.479       | 0.860         | 14.071 | 0.080        |
| DIT                                   | 1.806       | 0.348         | 9.376  | 0.482        |
| DIS & DIT                             | 9.611       | 2.482         | 37.212 | <b>0.001</b> |
| Constant                              | 3.741       | 0.550         | 25.474 | 0.178        |

Legend:

The dependent variable was OCB status (either positive or negative). Reference categories were <sup>1</sup> male sex and <sup>2</sup> no DIS & DIT. P-values <0.05 are marked bold. 95% CI is given for the Odd's ratio.

*Abbreviations:* CI, confidence interval; CSF, cerebrospinal fluid; DIS, dissemination in space; DIT, dissemination In time; SE, standard error; OCB, oligoclonal bands

**Table S10:** Binary logistic regression analysis to identify predictors of conversion to CDMS

| Variable                            | Odds ratio | 95% CI |        | P value      |
|-------------------------------------|------------|--------|--------|--------------|
| Sex <sup>1</sup>                    | 0.962      | 0.306  | 3.025  | 0.947        |
| Age (years)                         | 1.010      | 0.947  | 1.077  | 0.761        |
| Follow-up duration (years)          | 1.246      | 1.096  | 1.416  | <b>0.001</b> |
| Monocytes/ macrophages <sup>2</sup> | 7.314      | 1.401  | 38.197 | <b>0.018</b> |
| CSF pleocytosis <sup>3</sup>        | 2.872      | 1.005  | 8.204  | <b>0.049</b> |
| Constant                            | 0.962      | 0.306  | 3.025  | 0.142        |

Legend:

The dependent variable was occurrence of second relapse during follow-up (i.e. relapse or non-relapse). Reference categories were <sup>1</sup> male sex and <sup>2</sup> no monocytes/ macrophages (in CSF cytology) and <sup>3</sup> no CSF pleocytosis (i.e. WBC count <5/ $\mu$ l). P-values <0.05 are marked bold. 95% CI is given for the Odd's ratio.

*Abbreviations:* CI, confidence interval; CMDS, clinically definite multiple sclerosis; CSF, cerebrospinal fluid; WBC, white blood cell.

**Table S11:** Quantitative intrathecal immunoglobulin synthesis according to oligoclonal band status

|   | OCB negative |       | OCB positive |          |
|---|--------------|-------|--------------|----------|
|   | n            |       | n            |          |
| <b><i>Intrathecal IgG synthesis</i></b> |              |       |              |          |
| IF <sub>Reiber</sub> >0                 | 26           | 0 (0) | 494          | 353 (71) |
| IF <sub>Auer&amp;Hegen</sub> >0         | 26           | 0 (0) | 494          | 338 (68) |
| IgG index >0.7                          | 26           | 1 (4) | 494          | 356 (72) |
| <b><i>Intrathecal IgA synthesis</i></b> |              |       |              |          |
| IF <sub>Reiber</sub> >0                 | 26           | 1 (4) | 484          | 117 (24) |
| IF <sub>Auer&amp;Hegen</sub> >0         | 26           | 1 (4) | 484          | 73 (15)  |
| <b><i>Intrathecal IgM synthesis</i></b> |              |       |              |          |
| IF <sub>Reiber</sub> >0                 | 26           | 1 (4) | 494          | 172 (35) |
| IF <sub>Auer&amp;Hegen</sub> >0         | 26           | 1 (4) | 494          | 111 (22) |

Legend:

Data are shown as n (%). Abbreviations: IF, intrathecal fraction; Ig, immunoglobulin; OCB, oligoclonal bands